Pharma ETF (XPH) Hits a New 52-Week High

Group 1 - The State Street SPDR S&P Pharmaceuticals ETF (XPH) has reached a 52-week high, increasing 61.4% from its 52-week low of $35.22 per share [1] - The underlying index, S&P Pharmaceuticals Select Industry Index, represents the pharmaceuticals sub-industry within the broader S&P Total Markets Index, which includes all U.S. common stocks listed on major exchanges [1] - The ETF charges an annual fee of 35 basis points [1] Group 2 - The healthcare sector, particularly biotech stocks, is gaining traction due to innovations and increased mergers and acquisitions, amidst concerns over the AI bubble and a sluggish economy [2] - XPH currently holds a Zacks ETF Rank 3 (Hold) with a high-risk outlook, but it may continue to perform well in the near term, indicated by a positive weighted alpha of 39.32 [3]